ID   Mel1617-MR
AC   CVCL_DG53
SY   MEL1617-MR
DR   cancercelllines; CVCL_DG53
DR   GEO; GSM1199181
DR   Progenetix; CVCL_DG53
DR   Wikidata; Q54905153
RX   PubMed=24055054;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:75998; Trametinib (Mekinist; GSK1120212).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Omics: Array-based CGH.
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_DG51 ! Mel1617
SX   Male
AG   22Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 10
//
RX   PubMed=24055054; DOI=10.1016/j.celrep.2013.08.023;
RA   Villanueva J., Infante J.R., Krepler C., Reyes-Uribe P., Samanta M.,
RA   Chen H.-Y., Li B., Swoboda R.K., Wilson M., Vultur A.,
RA   Fukunaga-Kalabis M., Wubbenhorst B., Chen T.Y., Liu Q., Sproesser K.,
RA   DeMarini D.J., Gilmer T.M., Martin A.-M., Marmorstein R., Schultz D.C.,
RA   Speicher D.W., Karakousis G.C., Xu W., Amaravadi R.K., Xu X.-W.,
RA   Schuchter L.M., Herlyn M., Nathanson K.L.;
RT   "Concurrent MEK2 mutation and BRAF amplification confer resistance to
RT   BRAF and MEK inhibitors in melanoma.";
RL   Cell Rep. 4:1090-1099(2013).
//